A Phase II, Multi-Center, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of Lenalidomide (Revlimid) in Combination With Dexamethasone in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

Trial Profile

A Phase II, Multi-Center, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of Lenalidomide (Revlimid) in Combination With Dexamethasone in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 07 Dec 2015

At a glance

  • Drugs Dexamethasone; Lenalidomide
  • Indications Diffuse large B cell lymphoma
  • Focus Therapeutic Use
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 09 Sep 2009 Actual patient number (26) added as reported by ClinicalTrials.gov.
    • 12 May 2009 Planned end date changed from Jun 2008 to Dec 2008 as reported by ClinicalTrials.gov.
    • 09 Nov 2008 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top